WO2002095007A3 - Conjugates activated by cell surface proteases and therapeutic uses thereof - Google Patents

Conjugates activated by cell surface proteases and therapeutic uses thereof Download PDF

Info

Publication number
WO2002095007A3
WO2002095007A3 PCT/US2002/016819 US0216819W WO02095007A3 WO 2002095007 A3 WO2002095007 A3 WO 2002095007A3 US 0216819 W US0216819 W US 0216819W WO 02095007 A3 WO02095007 A3 WO 02095007A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
cell surface
therapeutic uses
surface proteases
activated
Prior art date
Application number
PCT/US2002/016819
Other languages
French (fr)
Other versions
WO2002095007A2 (en
Inventor
Edwin L Madison
Joseph Edward Semple
George P Vlasuk
Scott Jeffrey Kemp
Mallareddy Komandla
Daniel Vanna Siev
Original Assignee
Dendreon San Diego Llc
Edwin L Madison
Joseph Edward Semple
George P Vlasuk
Scott Jeffrey Kemp
Mallareddy Komandla
Daniel Vanna Siev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendreon San Diego Llc, Edwin L Madison, Joseph Edward Semple, George P Vlasuk, Scott Jeffrey Kemp, Mallareddy Komandla, Daniel Vanna Siev filed Critical Dendreon San Diego Llc
Priority to JP2002592470A priority Critical patent/JP2005518332A/en
Priority to EP02739474A priority patent/EP1545572A4/en
Priority to KR10-2003-7015240A priority patent/KR20040004642A/en
Priority to CA002447023A priority patent/CA2447023A1/en
Publication of WO2002095007A2 publication Critical patent/WO2002095007A2/en
Publication of WO2002095007A3 publication Critical patent/WO2002095007A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Conjugates, compositions and method for treatment, prevention, or amelioration of one or more symptoms of cell surface protease-related diseases, including MTSP-related, urokinase-type plasminogen activator (uPA) or endotheliase-related diseases, are provided. The conjugates for use in the compositions and methods are peptidic conjugates that contain therapeutic, including cytotoxic, agents.
PCT/US2002/016819 2001-05-23 2002-05-23 Conjugates activated by cell surface proteases and therapeutic uses thereof WO2002095007A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002592470A JP2005518332A (en) 2001-05-23 2002-05-23 Conjugates activated by cell surface proteases and their therapeutic use
EP02739474A EP1545572A4 (en) 2001-05-23 2002-05-23 Conjugates activated by cell surface proteases and therapeutic uses thereof
KR10-2003-7015240A KR20040004642A (en) 2001-05-23 2002-05-23 Conjugates activated by cell surface proteases and therapeutic uses thereof
CA002447023A CA2447023A1 (en) 2001-05-23 2002-05-23 Conjugates activated by cell surface proteases and therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29326701P 2001-05-23 2001-05-23
US60/293,267 2001-05-23

Publications (2)

Publication Number Publication Date
WO2002095007A2 WO2002095007A2 (en) 2002-11-28
WO2002095007A3 true WO2002095007A3 (en) 2005-05-06

Family

ID=23128397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/016819 WO2002095007A2 (en) 2001-05-23 2002-05-23 Conjugates activated by cell surface proteases and therapeutic uses thereof

Country Status (5)

Country Link
EP (1) EP1545572A4 (en)
JP (1) JP2005518332A (en)
KR (1) KR20040004642A (en)
CA (1) CA2447023A1 (en)
WO (1) WO2002095007A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9476037B2 (en) 2008-04-11 2016-10-25 Catalyst Biosciences, Inc. Factor VII polypeptides that are modified and uses thereof

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
AU2003252734A1 (en) * 2002-07-31 2004-02-16 Yamanouchi Pharmaceutical Co., Ltd. Novel serine protease
CA2535265C (en) 2003-08-22 2014-01-28 Dendreon Corporation Compositions and methods for the treatment of disease associated with trp-p8 expression
JP2008522632A (en) 2004-12-13 2008-07-03 アレシア・バイオセラピューティクス・インコーポレーテッド Polynucleotide and polypeptide sequences involved in the process of bone remodeling
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
HUE029650T2 (en) 2006-02-15 2017-02-28 Dendreon Pharmaceuticals Inc Small-Molecule modulators of TRP-P8 activity
US7772266B2 (en) 2006-02-15 2010-08-10 Dendreon Corporation Small-molecule modulators of TRP-P8 activity
KR100906145B1 (en) * 2006-05-30 2009-07-03 한국생명공학연구원 A anticancer drug comprising inhibitor of TMPRSS4
TWI369402B (en) 2006-07-05 2012-08-01 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
FR2906724B1 (en) 2006-10-04 2009-03-20 Sanofi Pasteur Sa METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US9869021B2 (en) 2010-05-25 2018-01-16 Aventa Technologies, Inc. Showerhead apparatus for a linear batch chemical vapor deposition system
EP2608251A4 (en) 2010-08-18 2014-01-15 Nat Inst Of Advanced Ind Scien Method of manufacturing organic semiconductor thin film and monocrystalline organic semiconductor thin film
EP2814807A4 (en) 2012-02-16 2015-10-07 Rqx Pharmaceuticals Inc Linear peptide antibiotics
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
BR112015001628A2 (en) 2012-07-25 2017-11-07 Catalyst Biosciences Inc modified factor x polypeptides and their use
BR112015012515B1 (en) 2012-11-30 2023-04-11 Sanofi Pasteur USE OF ANTIGENS, NUCLEIC ACID CONSTRUCTS OR VIRAL VECTORS CAPABLE OF EXPRESSING A VIRUS-LIKE PARTICLE (VLP) OF DENGUE AND A VACCINE AGAINST MEASLES, A VACCINE AGAINST MUMPS AND A VACCINE AGAINST RUBELLA
MY191366A (en) 2013-03-13 2022-06-20 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
CA3026074A1 (en) 2016-06-01 2017-12-07 M3 Biotechnology, Inc. N-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide compounds and their use to treat neurodegenerative diseases
CN111107870A (en) 2017-06-22 2020-05-05 催化剂生物科学公司 Modified membrane serine protease 1(MTSP-1) polypeptides and methods of use thereof
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
EP3932935A1 (en) * 2020-06-29 2022-01-05 Centre National de la Recherche Scientifique Antibacterial peptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972616A (en) * 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
WO2000053232A1 (en) * 1999-03-12 2000-09-14 Georgetown University Matriptase, a serine protease and its applications
US20020103133A1 (en) * 2000-03-15 2002-08-01 Copeland Robert A. Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
US20030180804A1 (en) * 2001-10-29 2003-09-25 Corvas International, Inc Solid phase synthesis of chemical libraries

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002113076A (en) * 1999-11-18 2004-03-10 Корвас Интернэшнл, Инк. (Us) Nucleic acids encoding endotheliases, endotheliases and their use
WO2003000201A2 (en) * 2001-06-25 2003-01-03 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
CA2475388A1 (en) * 2002-02-14 2003-08-21 William J. Rutter Chimeric molecules for cleavage in a treated host
AU2003269880A1 (en) * 2002-05-21 2003-12-22 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972616A (en) * 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
WO2000053232A1 (en) * 1999-03-12 2000-09-14 Georgetown University Matriptase, a serine protease and its applications
US20020103133A1 (en) * 2000-03-15 2002-08-01 Copeland Robert A. Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
US20030180804A1 (en) * 2001-10-29 2003-09-25 Corvas International, Inc Solid phase synthesis of chemical libraries

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1545572A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9476037B2 (en) 2008-04-11 2016-10-25 Catalyst Biosciences, Inc. Factor VII polypeptides that are modified and uses thereof

Also Published As

Publication number Publication date
CA2447023A1 (en) 2002-11-28
EP1545572A2 (en) 2005-06-29
JP2005518332A (en) 2005-06-23
EP1545572A4 (en) 2006-04-12
KR20040004642A (en) 2004-01-13
WO2002095007A2 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
WO2002095007A3 (en) Conjugates activated by cell surface proteases and therapeutic uses thereof
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
WO2004005326A3 (en) Tubulysin conjugates
DE60036017D1 (en) THROMBOLYSIS METHOD THROUGH LOCAL TREATMENT WITH REVERSIBLE INACTIVATED, ANNEALED PLASMINE
WO2006045119A3 (en) Improved inhibitors for the soluble epoxide hydrolase
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
WO2001096286A3 (en) Urokinase inhibitors
EP2189469A3 (en) Multicistronic siRNA constructs to inhibit tumors
CA2469343A1 (en) Combination of cytochome p450 dependent protease inhibitors
EP1790728A3 (en) Imaging, diagnosis and treatment of disease
WO2002044342A3 (en) Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof
WO2001070204A3 (en) Highly selective inhibitors of the urokinase plasminogen activator
AU2003243097A1 (en) Novel compounds
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
WO2003031585A3 (en) Transmembrane serine protease 25
WO2002005848A3 (en) Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
WO2003035688A3 (en) Targeted thrombosis by tissue factor polypeptides
HK1028876A1 (en) Pharmacuetical compositions comprising an aldose reductase inhibitor and an ace inhibitor
EP1825864A3 (en) Antithrombotic agents
AU2003259246A1 (en) Methods for the use of neurotoxin in the treatment of urologic disorders
WO2005053725A3 (en) Cancer treatment
WO2003053999A3 (en) Selective arylguanidine peptides as urokinase inhibitors
WO2001089558A3 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
WO2002066492A3 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 528002

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002312119

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2447023

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002592470

Country of ref document: JP

Ref document number: 1020037015240

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002739474

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002739474

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002739474

Country of ref document: EP